GH Research Q2 2025: strong cash position and 73% six-month remission in GH001 extension

GH Research (GHRS) — GH Research reported a Q2 2025 net loss of $9.3 million and cash of $308.7 million.

The company said its full open-label extension analysis for GH001 (inhaled 5-MeO-DMT) in treatment-resistant depression confirmed a 73% remission rate at six months without mandated psychotherapy and no treatment-related serious adverse events. It reiterated that only one topic remained on the GH001 IND clinical hold and that it planned to start its global pivotal program in 2026.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.